Chikungunya is an emerging mosquito-borne viral infection causing an increasing number of outbreaks in the tropics and subtropics, and smaller outbreaks have also been observed in temperate climates, including Europe.1 The infection has also become an ...
Chikungunya virus disease is associated with an increased risk of death for up to 84 days after symptom onset, including deaths from cerebrovascular diseases, ischaemic heart diseases, and diabetes. This study highlights the need for equitable access t...
Introduction of the R21/Matrix-M malaria vaccine could have a substantial public health benefit across sub-Saharan Africa.
Introduction of the R21/Matrix-M malaria vaccine could have a substantial public health benefit across sub-Saharan Africa.
Although malaria has placed a burden on humanity for centuries, affecting millions of people, particularly in Africa, numerous strategies and interventions have been implemented with varying degrees of success.1 The recent introduction of the R21/Matri...
Although malaria has placed a burden on humanity for centuries, affecting millions of people, particularly in Africa, numerous strategies and interventions have been implemented with varying degrees of success.1 The recent introduction of the R21/Matri...
Chikungunya virus is a mosquito-transmitted alphavirus first detected in Tanzania in the 1950s. However, it was only after a large outbreak in Réunion island that the risk of severe disease in humans started becoming clear.1 Outbreaks of chikungunya vi...
Chikungunya virus is a mosquito-transmitted alphavirus first detected in Tanzania in the 1950s. However, it was only after a large outbreak in Réunion island that the risk of severe disease in humans started becoming clear.1 Outbreaks of chikungunya vi...
Chikungunya virus disease is associated with an increased risk of death for up to 84 days after symptom onset, including deaths from cerebrovascular diseases, ischaemic heart diseases, and diabetes. This study highlights the need for equitable access t...
In their Comment, Robert L Gottlieb and Roger Paredes stated “deuteration is merely an artistic flourish, inconsequential to antiviral pharmacology. The drug would have the same effect regardless of deuteration.”1 This perspective, we argue, overlooks ...
To our knowledge, this is the first observational study describing the protective effect of rVSVΔG-ZEBOV-GP vaccination against death among patients with confirmed Ebola virus disease admitted to an Ebola health facility. Vaccination was protective aga...
SARS-CoV-2 causes persistent infections in a subset of individuals, which is a major clinical and public health problem that should be prioritised for further investigation for several reasons. First, persistent SARS-CoV-2 infection often goes unrecogn...
In the 40 years since the Ebola virus was first identified, there has been an increase in the size and frequency of epidemics of Ebola virus and other high-consequence pathogens. Although such health emergencies are often measured by numbers of infecti...
A fractional dose of the 17DD yellow fever vaccine induced an immunologic response with detectable titres at 5 years among the majority of participants in the Democratic Republic of the Congo. These findings support the use of fractional-dose vaccinati...
In 2016, major vaccine supply shortages during large yellow fever outbreaks in Africa prompted WHO to issue interim recommendations to use fractional dosing of yellow fever vaccines as a dose sparing strategy.1 Following this, one fifth of the standard...
Onradivir showed a safety profile comparable to placebo, as well as higher efficacy than placebo in ameliorating influenza symptoms and lowering the viral load in adult patients with uncomplicated influenza infection, especially the onradivir 600 mg on...